Factory 99% Dabigatran Etexilate Powder CAS 211915-06-9 Anti-Thrombotic Dabigatran Etexilate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A292
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Dabigatran Etexilate
• CAS: 211915-06-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Anti-Thrombotic
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Dabigatran Etexilate
Appearance	White Powder
CAS NO.	211915-06-9
Molecular Formula	C34H41N7O5
Storage	Keep in a cool, dry, dark location

 

Dabigatran Etexilate (also known as Dabigatran etexilate mesylate) is an orally active prodrug of Dabigatran. It is a reversible direct thrombin inhibitor (DTI) that specifically and reversibly inhibits both free and clot-bound thrombin.

 

 

1. Scientific Research: Dabigatran Etexilate is widely used in scientific research, particularly in the fields of molecular biology and pharmacology, for studying the mechanisms of thrombin inhibition and anticoagulation.
2. Pharmaceutical Development: It serves as a key compound in the development of anticoagulant drugs, offering a potential alternative to traditional anticoagulants.
3. In Vitro Experiments: Due to its specific inhibitory effect on thrombin, Dabigatran Etexilate is used in vitro to assess the anticoagulant activity of various compounds and to investigate the role of thrombin in coagulation processes.

1. Anticoagulation: Dabigatran Etexilate, upon conversion to Dabigatran, inhibits thrombin, thereby preventing the conversion of fibrinogen to fibrin, which is essential for blood clot formation. This function makes it useful in the treatment and prevention of thromboembolic events.
2. Reduction of Stroke Risk: By inhibiting thrombin, Dabigatran Etexilate reduces the risk of stroke and systemic embolism in patients with atrial fibrillation or other conditions that increase the risk of blood clots.
3. Fast Acting and Reversible: Dabigatran Etexilate exhibits a rapid onset of action and is reversible, allowing for more controlled anticoagulation therapy compared to some other anticoagulants.